Monograph
N03AE01 - Clonazepam |
Propably not porphyrinogenic |
PNP |
Rationale
Extensively CYP 3A4 metabolised. Conflicting references. Some clinical experience of non-porphyrinogenicity.
Chemical description
Benzodiazepine derivative used in attacks of epilepsy. Its effect is based on enhancement of normal GABa transmission. Extensively metabolized via CYP 3A4, the main metabolite being 7-amino-clonazepam. EPI-list: safe South African list: use with care French list: use The Merck Manual: unsafe Australian list: unsafe. Andersson; patient inquiry: used without illeffects (n=2) Peters: According to our experience probably not porphyrinogenic See: Suzuki 1992, Chaix 1997. C.Andersson; patient report: tolerated (n=1). Used in porphyria ward (Sweden).
IPNet drug reports
Uneventful use reported in 16 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
